<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775606</url>
  </required_header>
  <id_info>
    <org_study_id>ICE-001</org_study_id>
    <nct_id>NCT00775606</nct_id>
  </id_info>
  <brief_title>Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease</brief_title>
  <official_title>A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruth M. Rothstein CORE Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ideal anti-HIV medications for patients with advanced HIV disease is unknown. There is
      evidence that anti-HIV regimens that contain protease inhibitors can enhance immune function
      better than regimens that do not contain protease inhibitors. This is a study that will
      determine the difference in immune enhancement capabilities between an anti-HIV regimen that
      contains the protease inhibitor - lopinavir-ritonavir, and a regimen that contains efavirenz.
      Both medications are recommended as first line treatments for HIV-infected patients. This
      study will recruit HIV-positive patients that need to start anti-HIV treatment because their
      CD4+ T-cells are below 200. The usual threshold for starting treatment is a CD4+ T-cell less
      than 350. Subjects will be randomized to treatment with either an anti-HIV regimen that
      contains lopinavir-ritonavir or a regimen that contains efavirenz. The study will determine
      the difference in immune reconstitution over 24 weeks of treatment with study medications.
      Among the immune parameters that will be measured is the ability of each subject to respond
      to vaccination with the tetanus-diphtheria vaccine and the 23-valent pneumococcal vaccine.
      Both vaccines are also recommended for HIV-positive patients but HIV-positive patients tend
      to have a lower response rate to these vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on
      immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to efavirenz
      (EFV), in combination with daily emtricitabine (FTC)/tenofovir (TDF) as initial therapy for
      HIV-1 infection in HIV-infected treatment naïve subjects with CD4+ T-cells less than 200
      cells/ml.

      DURATION: Subjects will participate in ICE-001 for approximately 48 weeks after starting
      study treatment.

      SAMPLE SIZE: ICE-001 will enroll 60 subjects (30 per treatment arm).

      POPULATION: HIV-1-infected, antiretroviral (ARV) drug-naïve (≤7 days of ARV treatment at
      anytime prior to study entry) men and women between18 to 60 years of age with plasma HIV-1
      RNA levels &gt;1000 copies/mL and CD4+ T-cell counts &lt; 200 cells/ml obtained within 90 days
      prior to study entry.

      STRATIFICATION: Subjects will be stratified at screening based on plasma HIV-1 RNA levels
      &lt;100,000 and ≥100,000 copies/mL.

      REGIMEN: At entry subjects will be randomized to one of the following:

        -  ARM A: LPV 400 mg/RTV 100 mg BID + FTC 200 mg/TDF 300 mg QD

        -  ARM B: EFV 600 mg QD/FTC 200 mg/TDF 300 mg fixed dose combination QD

      The objective is to determine the differences in the degree of immune reconstitution in
      HIV-infected patients with a CD4+ T-cell count &lt; 200 cells/ml who initiated treatment with
      LPV/RTV + FTC/TDF compared to EFV/FTC/TDF.

      Study visits will occur at screening, pre-entry, entry and weeks 1, 4, 8, 12, 24 and 48 after
      study entry. Study medications will be provided at entry after randomization. At most study
      visits, clinical assessments, including histories, physical exams and determination of drug
      adherence, will occur. Blood for hematologic and metabolic safety assessments and for the
      assessment of immune parameters will be obtained. Immune parameters that will be measured
      include levels of T-cell apoptosis, maturation and activation. Frequencies of various T-cell
      subsets and other lymphocyte populations will also be done. Response to vaccination with
      tetanus-diphtheria vaccine and 23-valent pneumococcal polysaccharide vaccine (both given at
      week 8) will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4+ (Cluster of Differentiation 4) T-cell Apoptosis</measure>
    <time_frame>24 weeks from treatment initiation (baseline and week 24)</time_frame>
    <description>Change in the percentage of naive CD4 T-cells undergoing apoptosis as measured by propidium iodide staining. This is a lab test that measures the percentage of naive CD4 T-cells that are undergoing cell death. The change in this measure is obtained by determining the difference between the percentage of naive CD4 T-cells undergoing apoptosis at week 24 of treatment and the percentage undergoing apoptosis at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell Change</measure>
    <time_frame>24 weeks after treatment initiation (baseline and week 24)</time_frame>
    <description>This measures the change in CD4+ T-cells from baseline to week 24 of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Naive, Central Memory and Effector Memory CD4+ and CD8+ (Cluster of Differentiation 8) T-cell Frequency</measure>
    <time_frame>4, 12 and 24 weeks after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated and Regulatory CD4+ and CD8+ T-cell Frequencies</measure>
    <time_frame>4, 12 and 24 weeks after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Immunization With Pneumococcus Polysaccharide and Tetanus-diphtheria Vaccines</measure>
    <time_frame>4 weeks after treatment initiation</time_frame>
    <description>Response to immunization with pneumococcus polysaccharide and tetanus-diphtheria vaccines was not done due to small sample size</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Acquired Immune Deficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>ARM A/Lopinar/ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B/Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir 400 mg/ritonavir 100 mg</intervention_name>
    <description>Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD</description>
    <arm_group_label>ARM A/Lopinar/ritonavir</arm_group_label>
    <other_name>Kaletra</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD</description>
    <arm_group_label>ARM B/Efavirenz</arm_group_label>
    <other_name>Atripla</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infection

          2. The absence of exclusionary resistance mutations on a genotypic resistance assay

          3. Antiretroviral (ARV) drug-naïve

          4. Screening HIV-1 RNA &gt;1000 copies/mL

          5. Screening CD4+ T-cell count &lt; 200 cells/ml

          6. Laboratory values obtained within 30 days prior to study entry.

               -  Absolute neutrophil count (ANC) &gt;500/mm3

               -  Hemoglobin &gt;8.0 g/dL

               -  Platelet count &gt;40,000/mm3

               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase &lt;5 x ULN

               -  Total bilirubin &lt;2.5 x ULN

               -  Calculated creatinine clearance ≥60 mL/min (by Cockcroft-Gault equation)

          7. For women of reproductive potential, negative serum or urine pregnancy test within 48
             hours prior to initiating study medications.

          8. Contraception requirements

          9. Men and women age &gt;18 years and &lt; 60 years.

         10. Ability and willingness of subject or legal guardian/representative to give written
             informed consent.

        Exclusion Criteria:

          1. Currently breast-feeding.

          2. Use of immunomodulators, vaccines, growth hormone, systemic cytotoxic chemotherapy, or
             investigational therapy within 30 days prior to study entry.

          3. Known allergy/sensitivity to study drugs, pneumococcal polysaccharide vaccine,
             tetanus-diphtheria vaccine

          4. Receipt of pneumococcal polysaccharide vaccine or tetanus-diphtheria vaccine in the
             past 5 years.

          5. Active drug or alcohol use or dependence

          6. Serious illness requiring systemic treatment and/or hospitalization until candidate
             either completes therapy or is clinically stable on therapy, in the opinion of the
             site investigator, for at least 14 days prior to study entry.

          7. Requirement for any current medications that are prohibited with any study treatment.

          8. Evidence of any major resistance-associated mutation on any genotype or evidence of
             significant resistance on any phenotype performed at any time prior to study entry

          9. Current or anticipated imprisonment or involuntary incarceration in a medical facility
             for psychiatric or physical (e.g., infectious disease) illness

         10. History of, or current bipolar disorder, major depression, schizophrenia or other
             psychotic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan R. Tenorio, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <results_first_submitted>June 28, 2013</results_first_submitted>
  <results_first_submitted_qc>April 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2014</results_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Allan Tenorio, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>AIDS, HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects withdrew participation prior to starting study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ARM A/Lopinavir-ritonavir</title>
          <description>Subjects randomized to Arm a will initiate Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD</description>
        </group>
        <group group_id="P2">
          <title>ARM B/Efavirenz</title>
          <description>Subjects randomized to Arm B will initiate Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study sponsor terminated funding</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ARM A</title>
          <description>Subjects randomized to Arm a will initiate Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD</description>
        </group>
        <group group_id="B2">
          <title>ARM B</title>
          <description>Subjects randomized to Arm B will initiate Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="9.4"/>
                    <measurement group_id="B2" value="30.6" spread="7.1"/>
                    <measurement group_id="B3" value="33" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD4+ (Cluster of Differentiation 4) T-cell Apoptosis</title>
        <description>Change in the percentage of naive CD4 T-cells undergoing apoptosis as measured by propidium iodide staining. This is a lab test that measures the percentage of naive CD4 T-cells that are undergoing cell death. The change in this measure is obtained by determining the difference between the percentage of naive CD4 T-cells undergoing apoptosis at week 24 of treatment and the percentage undergoing apoptosis at baseline.</description>
        <time_frame>24 weeks from treatment initiation (baseline and week 24)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARM A/Lopinavir-ritonavir</title>
            <description>Subjects randomized to Arm a will initiate Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>ARM B/Efavirenz</title>
            <description>Subjects randomized to Arm B will initiate Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ (Cluster of Differentiation 4) T-cell Apoptosis</title>
          <description>Change in the percentage of naive CD4 T-cells undergoing apoptosis as measured by propidium iodide staining. This is a lab test that measures the percentage of naive CD4 T-cells that are undergoing cell death. The change in this measure is obtained by determining the difference between the percentage of naive CD4 T-cells undergoing apoptosis at week 24 of treatment and the percentage undergoing apoptosis at baseline.</description>
          <units>per cent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.33" spread="12.34"/>
                    <measurement group_id="O2" value="-8.01" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell Change</title>
        <description>This measures the change in CD4+ T-cells from baseline to week 24 of treatment.</description>
        <time_frame>24 weeks after treatment initiation (baseline and week 24)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARM A/Lopinavir-ritonavir</title>
            <description>Subjects randomized to Arm a will initiate Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>ARM B/Efavirenz</title>
            <description>Subjects randomized to Arm B will initiate Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Change</title>
          <description>This measures the change in CD4+ T-cells from baseline to week 24 of treatment.</description>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.83" spread="101.39"/>
                    <measurement group_id="O2" value="102.6" spread="150.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Naive, Central Memory and Effector Memory CD4+ and CD8+ (Cluster of Differentiation 8) T-cell Frequency</title>
        <time_frame>4, 12 and 24 weeks after treatment initiation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated and Regulatory CD4+ and CD8+ T-cell Frequencies</title>
        <time_frame>4, 12 and 24 weeks after treatment initiation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Immunization With Pneumococcus Polysaccharide and Tetanus-diphtheria Vaccines</title>
        <description>Response to immunization with pneumococcus polysaccharide and tetanus-diphtheria vaccines was not done due to small sample size</description>
        <time_frame>4 weeks after treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARM A</title>
            <description>Subjects randomized to Arm a will initiate Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>ARM B</title>
            <description>Subjects randomized to Arm B will initiate Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Immunization With Pneumococcus Polysaccharide and Tetanus-diphtheria Vaccines</title>
          <description>Response to immunization with pneumococcus polysaccharide and tetanus-diphtheria vaccines was not done due to small sample size</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 24</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ARM A/Lopinavir-ritonavir</title>
          <description>Subjects randomized to Arm a will initiate Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD</description>
        </group>
        <group group_id="E2">
          <title>ARM B/Efavirenz</title>
          <description>Subjects randomized to Arm B will initiate Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 elevation in ALT</sub_title>
                <description>Not related to study treatment. Related to alcohol use.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated due to the slow recruitment and the small number of subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Allan R. Tenorio</name_or_title>
      <organization>Rush University Medical Center</organization>
      <phone>312-942-3665</phone>
      <email>allan_s_tenorio@rush.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

